Back to top
more

PerkinElmer, Inc. (PKI)

(Delayed Data from NYSE)

$96.59 USD

96.59
692,880

+1.71 (1.80%)

Updated May 3, 2019 04:03 PM ET

After-Market: $96.59 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Top Ranked Growth Stocks to Buy for November 4th

by Zacks Equity Research

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, November 4th.

Here's Why Momentum Investors Will Love PerkinElmer (PKI)

by Zacks Equity Research

Does PerkinElmer (PKI) have what it takes to be a top stock pick for momentum investors? Let's find out.

PerkinElmer (PKI) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

PerkinElmer's (PKI) third-quarter results benefit from growth in Diagnostics segment. However, forex remains a woe.

Should You Buy PerkinElmer (PKI) Ahead of Earnings?

by Zacks Equity Research

PerkinElmer (PKI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is PerkinElmer (PKI) Outperforming Other Computer and Technology Stocks This Year?

by Zacks Equity Research

Is (PKI) Outperforming Other Computer and Technology Stocks This Year?

PerkinElmer (PKI) to Post Q3 Earnings: What's in the Offing?

by Zacks Equity Research

PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at Diagnostics segment.

    PerkinElmer (PKI) Earnings Expected to Grow: Should You Buy?

    by Zacks Equity Research

    PerkinElmer (PKI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Zacks.com featured highlights include: Vertex Pharmaceuticals, PerkinElmer, Stanley Black & Decker, 3M and Arthur J. Gallagher & Co

    by Zacks Equity Research

    Zacks.com featured highlights include: Vertex Pharmaceuticals, PerkinElmer, Stanley Black & Decker, 3M and Arthur J. Gallagher & Co

    Swayta Shah headshot

    Bet on These 5 Top-Ranked Stocks With Strong Sales Growth

    by Swayta Shah

    Robust sales growth is an important characteristic of potential stock market winners. Let's check out - Vertex Pharmaceuticals (VRTX), PerkinElmer (PKI), Stanley Black & Decker (SWK), 3M Company (MMM) and Arthur J. Gallagher (AJG) - as these are likely to see solid sales growth.

    Badger Meter (BMI) Q3 Earnings Top Estimates, Shares Gain

    by Zacks Equity Research

    Despite COVID-19 uncertainties, Badger Meter (BMI) witnesses solid third-quarter 2020 results with major rise in both top and bottom lines on the back of consistent demand across most end markets.

    PerkinElmer (PKI) Is Up 4.11% in One Week: What You Should Know

    by Zacks Equity Research

    Does PerkinElmer (PKI) have what it takes to be a top stock pick for momentum investors? Let's find out.

    Why PerkinElmer (PKI) is Poised to Beat Earnings Estimates Again

    by Zacks Equity Research

    PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    3 Reasons Why Growth Investors Shouldn't Overlook PerkinElmer (PKI)

    by Zacks Equity Research

    PerkinElmer (PKI) possesses solid growth attributes, which could help it handily outperform the market.

    Is PerkinElmer (PKI) Stock Outpacing Its Computer and Technology Peers This Year?

    by Zacks Equity Research

    Is (PKI) Outperforming Other Computer and Technology Stocks This Year?

    Baxter's Clinimix and Clinimix E Injections Receive FDA Nod

    by Zacks Equity Research

    Baxter's (BAX) Clinimix and Clinimix E with Higher Protein Injection received FDA approval, which will help clinicians to improve care for critically ill patients.

    Here's Why You Should Avoid Betting on Intuitive Surgical Now

    by Zacks Equity Research

    Intense competition in the global MedTech space and weak operational performance weighs on Intuitive Surgical (ISRG).

    Veeva's Offering Chosen by Idorsia to Drive Digital Engagement

    by Zacks Equity Research

    Veeva Systems' (VEEV) Commercial Cloud selected by Idorsia to enhance its digital field force in the United States, Japan and countries across Europe.

    Zacks.com featured highlights include: PKI, KLAC, TRU, UGI and TKR

    by Zacks Equity Research

    Zacks.com featured highlights include: PKI, KLAC, TRU, UGI and TKR

    PRA Health (PRAH) Enters Into Strategic Deal With Deep Lens

    by Zacks Equity Research

    PRA Health's (PRAH) deal with Deep Lens can help detect and match oncology patients to suitable clinical trials and best precision therapies.

    Here's Why You Should Retain Cooper Companies (COO) Stock

    by Zacks Equity Research

    Cooper Companies (COO) continues to benefit from solid CVI and CSI product portfolios.

    Swayta Shah headshot

    5 Stocks With Attractive Sales Growth to Invest in Now

    by Swayta Shah

    Solid sales growth is a major characteristic of potential winners. The firms that put more emphasis on sales management have a competitive advantage, as strong sales usually get converted into growth.

    Is PerkinElmer (PKI) Outperforming Other Computer and Technology Stocks This Year?

    by Zacks Equity Research

    Is (PKI) Outperforming Other Computer and Technology Stocks This Year?

    Here's Why You Should Retain McKesson (MCK) Stock for Now

    by Zacks Equity Research

    McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.

    Here's Why You Should Invest in AMN Healthcare (AMN) Stock

    by Zacks Equity Research

    AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP.

    Varian (VAR) Expands Presence With Germany's Ethos Order

    by Zacks Equity Research

    Varian's (VAR) Ethos therapy is being adopted in Germany, thus expanding the company's geographic footprint.